Neurocrine Biosciences | Frais De Vente Et D'Administration



Selling And Administration Expenses Changement Date
AbbVie USD 3.29B 562M 2025-03
Acadia Pharmaceuticals USD 126.37M 3.71M 2025-03
Agios Pharmaceuticals USD 41.53M 10.17M 2025-03
ALKERMES USD 171.7M 24.71M 2025-03
Alnylam Pharmaceuticals USD 239.95M 55.39M 2025-03
Amgen USD 1.69B 191M 2025-03
Biogen USD 572.5M 104.8M 2025-03
BioMarin Pharmaceutical USD 206.12M 50.65M 2025-03
Cytokinetics USD 57.37M 4.97M 2025-03
Dynavax Technologies USD 106.33M 64.74M 2025-03
Exelixis USD 134.33M 22.53M 2025-01
Gilead Sciences USD 1.26B 603M 2025-03
Halozyme Therapeutics USD 42.36M 113K 2025-03
Incyte USD 325.69M 1.02M 2025-03
Ionis Pharmaceuticals USD 76M 12.08M 2025-03
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Pfizer USD 3.01B 1.27B 2025-03
Prothena USD 16.85M 88K 2024-12
Regeneron Pharmaceuticals USD 633M 159.2M 2025-03
Repligen USD 71.26M 10.93M 2025-03
Sarepta Therapeutics USD 133.63M 30.24M 2025-03
Teva Pharmaceutical Industries USD 919M 33M 2025-03
Ultragenyx Pharmaceutical USD 87.8M 5.3M 2025-03
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12



Neurocrine Biosciences Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.